Last updated: February 13, 2026
What Is NDC 00456-2410?
National Drug Code (NDC) 00456-2410 corresponds to a specific pharmaceutical product. Based on available data, it identifies Aptivus (tipranavir), an antiretroviral used to treat HIV-1 infection. This drug is part of the protease inhibitor class, designated for patients who have shown resistance or intolerance to other treatments.
Market Overview of Aptivus (tipranavir)
Current Market Size
- Global HIV/AIDS therapeutics market valued at approximately $28 billion in 2022 (source: IQVIA).
- Aptivus accounts for a fraction of this, with sales primarily in the U.S., Europe, and select markets in Asia.
- Estimated sales for tipranavir products worldwide hovered around $150 million in 2022 (source: Evaluate Pharma).
Competitive Landscape
- Main competitors include other protease inhibitors such as darunavir, atazanavir, and lopinavir.
- Market share of tipranavir has declined over the past five years due to newer agents with better tolerability profiles and simpler dosing regimens.
- Patent status: Patents expired in 2017, leading to increased generic competition, which compresses prices and market exclusivity.
Regulatory Status
- Approved by the FDA in 2005.
- No recent label extensions or new indications.
- Generic versions approved post-2017, affecting market positioning.
Price Trends and Projections
Historical Pricing
- Brand-name price (2017): Approximately $2,000 per 30-day supply.
- Post-generic entry: Prices fell to approximately $1,200 per 30-day supply.
- Current average retail price: Ranges from $900 to $1,100 per 30-day supply (source: Drugs.com).
Future Price Drivers
- Generic Competition: Increases in generic supply lead to further price reductions.
- Market Penetration: Adoption in low-income countries remains limited due to cost and distribution challenges.
- Healthcare Policy: Rebate policies and negotiated discounts could lower net prices.
- Patent and Exclusivity: Patent expiry in 2017 opened markets but offers no new exclusivity; prices are unlikely to recover to original levels.
Projected Pricing (Next 5 Years)
| Year |
Estimated Price per 30-day Supply |
Notes |
| 2023 |
$900 |
Continued generic competition |
| 2024 |
$850 |
Potential discounts, increased availability |
| 2025 |
$800 |
Market stabilization, further generic entry |
| 2026 |
$750 |
Price pressure persists |
| 2027 |
$700 |
Possible shift due to newer therapies |
Revenue Forecasts
- Market volume assumption: Approximately 1 million treatment units annually worldwide.
- Estimated revenue contribution: Based on a $900 average price, annual global sales volume could generate about $900 million in total.
- Tipranavir’s market share expected below 10%, resulting in $80-100 million annually.
Stock and Investment Implications
- A decline in revenue due to generic competition affects overall profitability of companies with substantial tipranavir portfolios.
- Companies with diversified HIV drug offerings or innovative pipeline assets are less impacted.
- Patent litigation or regulatory barriers are unlikely to alter current price trends.
Key Takeaways
- NDC 00456-2410 corresponds to Aptivus (tipranavir), with a mature market primarily driven by generic competition.
- Market size remains significant but contracting; current sales are ~$100 million annually.
- Prices have declined substantially since patent expiry, with future prices stabilizing around $700–$900 per 30-day supply.
- The market outlook suggests further price compression, driven by generics and newer therapies.
- Revenue projections for tipranavir are expected to decline in the next five years, affecting stakeholders with vested interests in this drug.
FAQs
1. What is the main factor influencing the pricing of NDC 00456-2410?
Patent expiry and subsequent generic competition primarily drive the price reduction.
2. How does tipranavir compare to other HIV protease inhibitors?
It is less preferred due to its side effect profile and dosing complexity, which has diminished its market share.
3. Are there ongoing efforts to extend the patent or introduce new formulations?
No recent patents or formulations are under development; focus shifts to newer agents with improved profiles.
4. Which regions represent growth opportunities despite market saturation?
Low-income regions with limited access to newer medications still present growth potential, but cost remains a barrier.
5. Will pricing improve with new drug approvals?
Not likely; newer drugs often establish higher pricing or positional advantage, further reducing tipranavir’s market share.
Sources
- IQVIA. "Global HIV/AIDS Therapeutics Market Data," 2022.
- Evaluate Pharma. "Top HIV Drugs by Sales," 2022.
- Drugs.com. "Tipranavir (Aptivus) Prices," 2023.
- FDA Label Archives. "Aptivus (Tipranavir) Approval History," 2005.
- Pharmaceutical Patent Database. "Patent Expiry Dates for Tipranavir," 2017.
